DIAMONDBACK DRUGS

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2010–2019

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2019	—	1	1
2018	—	4	1
2017	—	4	1
2016	—	4	1
2015	—	4	1
2014	—	4	1
2013	—	6	2
2012	—	4	1
2011	—	4	1
2010	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
ROCK & ASSOCIATES	—	25
PARRY, ROMANI, DECONCINI & SYMMS	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	35
SENATE	35

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	38
Health Issues	Health Issues	38
Law Enforcement/Crime/Criminal Justice	Law Enforcement/Crime/Criminal Justice	23
Budget/Appropriations	Budget/Appropriations	20
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	18

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1625115th Congress

Consolidated Appropriations Act, 2018

2018 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 1625

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 1625115th Congress

Consolidated Appropriations Act, 2018

2018 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 1625

Show 21 more cited filings

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 1625115th Congress

Consolidated Appropriations Act, 2018

2018 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 1625

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 1625115th Congress

Consolidated Appropriations Act, 2018

2018 · first_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations to fund the FDA implementation of compounding pharmacy regulations; H.R. 1625, Consolidated Appropriations Act, 2018.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 1625

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · first_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2018 · first_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Controlled substance issues pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 2871115th Congress

Preserving Patient Access to Compounded Medications Act of 2017

2017 · second_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations for FDA for FY2017 and FY2018. H.R. 2871, Patient Access to Compounded Medications Act of 2017.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 2871

H.R. 5054114th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017

2016 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 5054

S. 1406114th Congress

Saving Access to Compounded Medications for Special Needs Patients Act

2016 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.

Client expense: — · Firm income: $11,250

Matched citations: S.1406

S. 2956114th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017

2016 · fourth_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.

Client expense: — · Firm income: $11,250

Matched citations: S. 2956

H.R. 5054114th Congress

Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017

2016 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Appropriations (H.R. 5054 and S. 2956) to fund the FDA implementation of compounding pharmacy regulations.

Client expense: — · Firm income: $11,250

Matched citations: H.R. 5054

S. 1406114th Congress

Saving Access to Compounded Medications for Special Needs Patients Act

2016 · third_quarter · Firm: ROCK & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act.

Client expense: — · Firm income: $11,250

Matched citations: S.1406

Source: Senate LDA

DIAMONDBACK DRUGS — Lobbying Disclosure | Poliscope